---

---

tags : Therapeutics    crawled time : 16:20   

save search

---

Antibody Therapeutics Market Size to Grow USD 364180 Million by 2029 at a CAGR of 11% | Valuates Reports
Published: 2024-01-21 (Crawled : 16:20) - prnewswire.com
JNJ | News | $146.39 0.45% 1.8M |

Health Technology

| Email alert Add to watchlist
AZNCF | $138.24 800 |

Health Technology

| Email alert Add to watchlist
AZN | $68.545 0.27% 1.2M |

Health Technology

| Email alert Add to watchlist
antibody million therapeutics market

---

Calliditas Therapeutics appoints Maria Törnsén as President North America
Published: 2024-01-07 (Crawled : 16:20) - prnewswire.com
SNY | News | $46.34 2.09% 620K |

Health Technology

| Email alert Add to watchlist
SNYNF | News | $92.7 600K |

Health Technology

| Email alert Add to watchlist
CALT | News | $17.65 1.2K |

Health Technology

| Email alert Add to watchlist
america therapeutics

---

Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023
Published: 2023-12-10 (Crawled : 16:20) - globenewswire.com
JSPR | $23.13 -0.35% 8.1K |

| Email alert Add to watchlist
presentation positive cell aml therapeutics results study

---

Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023
Published: 2023-11-04 (Crawled : 16:20) - globenewswire.com
VERA | $38.72 -1.93% 240K |

Professional, Scientific, and T...

| Email alert Add to watchlist
kidney origin positive week therapeutics study

---

Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
Published: 2023-10-21 (Crawled : 16:20) - globenewswire.com
HARP | $23.01 0.07% 6.6M |

Health Technology

| Email alert Add to watchlist
hpn328 congress cell trial therapeutics response

---

Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) Congress
Published: 2023-06-17 (Crawled : 16:20) - globenewswire.com
VERA | $38.72 -1.93% 240K |

Professional, Scientific, and T...

| Email alert Add to watchlist
association renal presentation origin positive week trial therapeutics results igan

---

Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)
Published: 2023-06-11 (Crawled : 16:20) - globenewswire.com
NTLA | $21.41 0.42% 210K |

Health Technology

| Email alert Add to watchlist
ntla-2002 crispr positive treatment therapeutics study

---

Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023
Published: 2023-06-10 (Crawled : 16:20) - globenewswire.com
CLDX | $37.65 -2.28% 84K |

Health Technology

| Email alert Add to watchlist
urticaria positive program therapeutics

---

Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting
Published: 2023-06-03 (Crawled : 16:20) - globenewswire.com
ELTX | $8.23 9.4K |

| Email alert Add to watchlist
eli-002 asco positive cancer pancreatic risk meeting therapeutics study

---

Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2023-06-03 (Crawled : 16:20) - globenewswire.com
ALLO | $3.505 1.3% 290K |

Health Technology

| Email alert Add to watchlist
allo-501 cell meeting therapeutics

---

Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
Published: 2023-02-26 (Crawled : 16:20) - globenewswire.com
CLDX | $37.65 -2.28% 84K |

Health Technology

| Email alert Add to watchlist
urticaria therapeutics positive study

---

Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition
Published: 2022-12-11 (Crawled : 16:20) - prnewswire.com
PSTX | News | $2.04 2.0% 120K |

Health Technology

| Email alert Add to watchlist
fviii-101 preclinical meeting therapeutics therapy

---

Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
Published: 2022-12-11 (Crawled : 16:20) - globenewswire.com
HARP | $23.01 0.07% 6.6M |

Health Technology

| Email alert Add to watchlist
hpn217 therapeutics

---

Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting
Published: 2022-12-11 (Crawled : 16:20) - globenewswire.com
KYMR | $34.82 -0.85% 93K |

Health Technology

| Email alert Add to watchlist
kt-253 preclinical meeting leukemia therapeutics acute myeloid leukemia

---

Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting
Published: 2022-12-10 (Crawled : 16:20) - globenewswire.com
FATE | $4.91 -2.58% 370K |

Health Technology

| Email alert Add to watchlist
meeting t-cell therapeutics therapy

---

Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead of Autologous Transplant
Published: 2022-12-10 (Crawled : 16:20) - globenewswire.com
BEAM | $24.35 0.17% 280K |

Health Technology

| Email alert Add to watchlist
disease preclinical therapeutics platform

---

LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
Published: 2022-12-10 (Crawled : 16:20) - globenewswire.com
LVTX | $2.735 -3.36% 84K |

| Email alert Add to watchlist
lava-051 meeting trial therapeutics phase 1

---

Plus Therapeutics Provides Updates on ReSPECT™ Clinical Trials at the 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
Published: 2022-11-19 (Crawled : 16:20) - globenewswire.com
PSTV | $1.67 -1.27% 1.9K |

Health Technology

| Email alert Add to watchlist
day trials education meeting therapeutics plus

---

Lyra Therapeutics Announces Additional Data Presentations from Phase 2 LANTERN Study at the American Rhinologic Society Annual Meeting
Published: 2022-09-10 (Crawled : 16:20) - prnewswire.com
LYRA | $5.425 0.65% 34K |

Health Technology

| Email alert Add to watchlist
meeting therapeutics study phase 2

---

SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022
Published: 2022-09-10 (Crawled : 16:20) - globenewswire.com
SWTX | News | $40.555 -4.51% 180K |

Health Technology

| Email alert Add to watchlist
trial therapeutics

---

Gainers vs Losers

79%

21%

Top 10 Gainers

AGBA | News | $1.22 205.0% 86M |

Finance

EGOX | $0.0606 68.33% 250M |

NVFY | $3.45 63.51% 20M |

Consumer Durables

ZCMD | $1.98 36.55% 27M |

Commercial Services

CHRO | $1.66 35.51% 70K |

n/a

INDO | $5.43 33.09% 10M |

Energy Minerals

PAPL | $2.07 26.22% 550K |

RWOD | $10.08 26.05% 5.6M |

n/a

AULT | $0.304 25.57% 47M |

Manufacturing

HUSA 4 | $2.07 23.95% 2.1M |

Energy Minerals

---

Your saved searches

---